Teva’s Complex Generic Ambitions Number Nearly A Dozen In 2021

As Israeli Firm Publishes Full-Year Results

 
• By Dean Rudge

Israeli giant Teva is hoping to follow the recent big-ticket launches of generic Truvada/Atripla and NuvaRing with multiple complex generics launches in the US this year. Management discussed individual product opportunities as Teva disclosed full-year financial earnings.

US Flag
Teva's generic operations in the US are worth around $4bn per year in revenues • Source: Shutterstock

More from Generics

More from Products